Published in:

09-05-2024 | Myasthenia Gravis | Review Article

FcRn Inhibitor Therapies in Neurologic Diseases

Authors: Nouf Alfaidi, Salama Karmastaji, Alexandria Matic, Vera Bril

Published in: CNS Drugs | Issue 6/2024

Abstract

In the last decade, the landscape of treating autoimmune diseases has evolved with the emergence and approval of novel targeted therapies. Several new biological agents offer selective and target-specific immunotherapy and therefore fewer side effects, such as neonatal Fc receptor (FcRn)-targeting therapy. Neonatal Fc receptor-targeted therapies are engineered to selectively target FcRn through various methods, such as Fc fragments or monoclonal anti-FcRn antibodies. These approaches enhance the breakdown of autoantibodies by blocking the immunoglobulin G recycling pathway. This mechanism reduces overall plasma immunoglobulin levels, including the levels of pathogenic autoantibodies, without affecting the other immunoglobulin class immunoglobulin A, immunoglobulin E, immunoglobulin M, and immunoglobulin D levels. Drugs that inhibit FcRn include efgartigimod, rozanolixizumab, batoclimab, and nipocalimab. These medications can be administered either intravenously or subcutaneously. Numerous clinical trials are currently underway to investigate their effectiveness, safety, and tolerability in various neurological conditions, including myasthenia gravis and other neurological disorders such as chronic inflammatory demyelinating polyneuropathy, myositis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. Positive results from clinical trials of efgartigimod and rozanolixizumab led to their approval for the treatment of generalized myasthenia gravis. Additional clinical trials are still ongoing. Neonatal Fc receptor inhibitor agents seem to be well tolerated. Reported adverse events include headache (most commonly observed with efgartigimod and rozanolixizumab), upper respiratory tract infection, urinary tract infection, diarrhea, pyrexia, and nausea. Additionally, some of these agents may cause transient hypoalbuminemia and hypercholesterolemia notably reported with batoclimab and nipocalimab. In this review, we discuss the available clinical data for FcRN inhibitor agents in treating different neurological autoimmune diseases.

Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. https://doi.org/10.1038/nri2155.CrossRefPubMed

Borvak J. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998;10(9):1289–98. https://doi.org/10.1093/intimm/10.9.1289.CrossRefPubMed

Rath T, Kuo T T, Baker K, et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol. 2013;33(S1):9–17. https://doi.org/10.1007/s10875-012-9768-y.CrossRef

Chiu ML, Goulet DR, Teplyakov A, et al. Antibody structure and function: the basis for engineering therapeutics. Antibodies. 2019;8(4):55. https://doi.org/10.3390/antib8040055.CrossRefPubMedPubMedCentral

Lozano NA, Lozano A, Marini V, et al. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. Am J Reprod Immunol. 2018;80(3): e12972. https://doi.org/10.1111/aji.12972.CrossRefPubMedPubMedCentral

Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. https://doi.org/10.1038/nri2206.CrossRefPubMed

Baldwin WM, Valujskikh A, Fairchild RL. The neonatal Fc receptor: key to homeostasic control of IgG and IgG-related biopharmaceuticals. Am J Transplant. 2019;19(7):1881–7. https://doi.org/10.1111/ajt.15366.CrossRefPubMedPubMedCentral

Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14:175628642199738. https://doi.org/10.1177/1756286421997381.CrossRef

Zuercher AW, Spirig R, Baz Morelli A, et al. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10): 102366. https://doi.org/10.1016/j.autrev.2019.102366.CrossRefPubMed

10.

Heo Y-A. Efgartigimod: first approval. Drugs. 2022;82(3):341–8. https://doi.org/10.1007/s40265-022-01678-3.CrossRefPubMedPubMedCentral

11.

Hoy SM. Rozanolixizumab: first approval. Drugs. 2023;83(14):1341–7. https://doi.org/10.1007/s40265-023-01933-1.CrossRefPubMedPubMedCentral

12.

Zisimopoulou P, Evangelakouet P, Tzartosal J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–45. https://doi.org/10.1016/j.jaut.2013.12.004.CrossRefPubMed

13.

Bhandari V, Bril V. FcRN receptor antagonists in the management of myasthenia gravis. Front Neurol. 2023;14:1229112. https://doi.org/10.3389/fneur.2023.1229112.CrossRefPubMedPubMedCentral

14.

Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865–87. https://doi.org/10.1007/s40265-022-01726-y.CrossRefPubMedPubMedCentral

15.

Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor–related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123(12):5190–202. https://doi.org/10.1172/JCI66039.CrossRefPubMedPubMedCentral

16.

Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(1):30. https://doi.org/10.1038/s41572-019-0079-y.CrossRef

17.

Tüzün E, Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev. 2013;12(9):904–11. https://doi.org/10.1016/j.autrev.2013.03.003.CrossRefPubMed

18.

Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263(4):826–34. https://doi.org/10.1007/s00415-015-7963-5.CrossRefPubMed

19.

Phillips WD, Vincent A. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res. 2016;5:1513. https://doi.org/10.12688/f1000research.8206.1.CrossRef

20.

Bril V, Silvestri NJ, Barnett-Tapia C. A review of disease mechanisms and current and emerging treatment options for generalized myasthenia gravis. Prim Care Companion CNS Disord. 2022;24(3):AR21018WC2C. https://doi.org/10.4088/PCC.AR21018WC2C.CrossRefPubMed

21.

Bayry J, Ahmed E, Toscano-Rivero D, et al. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J Allergy Clin Immunol Pract. 2023;11(6):1688–97. https://doi.org/10.1016/j.jaip.2023.04.002.CrossRefPubMed

22.

Barnett C, Tabasinejad R, Bril V. Current pharmacotherapeutic options for myasthenia gravis. Expert Opin Pharmacother. 2019;20(18):2295–303. https://doi.org/10.1080/14656566.2019.1682548.CrossRefPubMed

23.

Sánchez-Tejerina D, Sotoca J, Llaurado A, et al. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med. 2022;11(21):6394. https://doi.org/10.3390/jcm11216394.CrossRefPubMedPubMedCentral

24.

Richter WO, Donner MG, Selmaier A, et al. Efficacy and safety of immunoglobulin apheresis. ASAIO J. 1997;43(1):53–9.CrossRefPubMed

25.

Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. 2020;10:3052. https://doi.org/10.3389/fimmu.2019.03052.CrossRefPubMedPubMedCentral

26.

Vaccaro C, Zhou J, Ober RJ, et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–8. https://doi.org/10.1038/nbt1143.CrossRefPubMed

27.

Argenx announces U.S. Food and Drug Administration approval of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis. Press release. Argenx; 20 June, 2023.

28.

European panel recommends under-the-skin efgartigimod for gMG, September 19, 2023. Available from: https://myastheniagravisnews.com/news/european-panel-recommends-under-the-skin-efgartigimod-for-gmg/#:~:text=A%20European%20Medicines%20Agency%20(EMA,against%20acetylcholine%20receptors%20(AChRs). Accessed 27 Apr 2024.

29.

Argenx announces approval of Vyvudura^® (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in Japan for generalized myasthenia gravis, Jan 17, 2024. Available at: https://ir.zailaboratory.com/news-releases/news-release-details/argenx-announces-approval-vyvdurar-efgartigimod-alfa-and. Accessed 27 Apr 2024.

30.

Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–86. https://doi.org/10.1172/JCI97911.CrossRefPubMedPubMedCentral

31.

Howard JF, Bril V, Burns T, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–7. https://doi.org/10.1212/WNL.0000000000007600.CrossRefPubMedPubMedCentral

32.

Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–36. https://doi.org/10.1016/S1474-4422(21)00159-9.CrossRefPubMed

33.

Saccà F, Barnett C, Vu T, et al. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). J Neurol. 2023;270(4):2096–105. https://doi.org/10.1007/s00415-022-11517-w.CrossRefPubMedPubMedCentral

34.

Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9(414):eaan1208. https://doi.org/10.1126/scitranslmed.aan1208.CrossRefPubMed

35.

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for priority review. UCB News press release. Brussels, Belgium, January 6, 2023. Available from: https://www.ucb.com/stories-media/press-releases/article/UCB-announces-rozanolixizumab-BLA-for-the-treatment- of-generalized-myasthenia-gravis-filed-with-US-FDA-and-designated-for-Priority- Review#:~:text=Brussels%20(Belgium)%206%20Jan%202023,that%20the%20Agency% 20has%20granted. Accessed 18 Nov 2023.

36.

UCB announces approval of Rystiggo^® (rozanolixizumab) and Zilbrysq^® (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan, UCB press release, Brussels (Belgium), 25 September 2023. Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan. Accessed 27 Apr 2024.

37.

UCB announces European Commission approval of RYSTIGGO (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe, UBC press release, Brussels (Belgium).8 January 2024. Available from: https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-European-Commission-approval-of-RYSTIGGORV-rozanolixizumab-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-in-Europe. Accessed 27 Apr 2024.

38.

Kaplan AA. Therapeutic plasma exchange: a technical and operational review. J Clin Apheresis. 2013;28(1):3–10. https://doi.org/10.1002/jca.21257.CrossRefPubMed

39.

Ohkubo A, Okado T, Kurashima N, et al. Removal characteristics of immunoglobulin G subclasses by conventional plasma exchange and selective plasma exchange. Ther Apher Dial. 2015;19(4):361–6. https://doi.org/10.1111/1744-9987.12346.CrossRefPubMed

40.

Bril V, Benatar M, Andersen H, et al. Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: a phase 2 RCT. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000011108.CrossRefPubMedPubMedCentral

41.

Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383–94. https://doi.org/10.1016/S1474-4422(23)00077-7.CrossRefPubMed

42.

Harbour BioMed announces biologics license application acceptance of batoclimab for treatment of generalized myasthenia gravis by NMPA. 29 Jun, 2023. Available from: https://www.prnewswire.com/news-releases/harbour-biomed-announces-biologics-license-application-acceptance-of-batoclimab-for-treatment-of-generalized-myasthenia-gravis-by-nmpa-301866990.html. Accessed 27 Apr 2024.

43.

Collins JC, Jones L, Snyder M, et al. RVT-1401, a novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration (P5.2-079). Neurology. 2019;92.

44.

Yap DYH, Hai J, Lee P, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci. 2021;14(5):1769–79. https://doi.org/10.1111/cts.13019.CrossRefPubMedPubMedCentral

45.

Yan C, Duan R S, Yang H, et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022;11(2):815–34. https://doi.org/10.1007/s40120-022-00345-9.CrossRefPubMedPubMedCentral

46.

Benatar M, Wiendl H, Nowak R, et al. Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurol Open. 2024;6(1): e000536. https://doi.org/10.1136/bmjno-2023-000536.CrossRefPubMedPubMedCentral

47.

Ling LE, Hillson J L, Tiessen R G, et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther. 2019;105(4):1031–9. https://doi.org/10.1002/cpt.1276.CrossRefPubMed

48.

Vivacity-GM. A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis. Santiago Arroyo Neurol. 2021;96:2157.

49.

Johnson & Johnson reports positive topline results for nipocalimab from a phase 3 pivotal study in generalized myasthenia gravis (gMG) and a phase 2 study in Sjögren’s disease (SjD), Spring House, Pa.,February 5, 2024. Available from: https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-positive-topline-results-for-nipocalimab-from-a-phase-3-pivotal-study-in-generalized-myasthenia-gravis-gmg-and-a-phase-2-study-in-sjogrens-disease-sjd. Accessed 27 Apr 2024.

50.

Ramchandren S, Sanga P, Burcklen M, et al. Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia travis. Neurology. 2022. https://doi.org/10.1212/01.wnl.0000903328.46907.49.CrossRef

51.

Yan C, Yue Y, Guan Y, et al. Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2024. https://doi.org/10.1001/jamaneurol.2024.0044.CrossRefPubMedPubMedCentral

52.

Briani C, Visentin A. Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies. Neurotherapeutics. 2022;19(3):874–84. https://doi.org/10.1007/s13311-022-01222-x.CrossRefPubMedPubMedCentral

53.

Sivadasan A, Bril V. Therapies in autoimmune peripheral neuropathies beyond intravenous immunoglobulin, plasma exchange and corticosteroids: an analytical review. Transfus Med Rev. 2022;36(4):220–9. https://doi.org/10.1016/j.tmrv.2022.05.002.CrossRefPubMed

54.

Nelke C, Spatola M, Schroeter CB, et al. Neonatal Fc receptor- targeted therapies in neurology. Neurotherapeutics. 2022;19(3):729–40. https://doi.org/10.1007/s13311-021-01175-7. (Epub 2022 Jan 7).CrossRefPubMedPubMedCentral

55.

Argenx reports positive topline data from ADHERE study of VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy. Amsterdam, The Netherlands, July 17, 2023. Available from: https://www.argenx.com/sites/default/files/media-documents/Press-Release_ARGX_ADHERE_Data_Release.pdf. Accessed 1 Dec 2023.

56.

Querol L, de Seze J, Dysgaard T, et al. Rozanolixizumab in chronic inflammatory demyelinating polyradiculoneuropathy: randomized subject-/investigator-blind placebo-controlled phase 2a trial. In: Peripheral Nerve Society Annual Meeting 2022 Abstract Supplement. J Peripheral Nerv Syst. 2022;27(S3):S4–183; abstract 66b.

57.

Janssen Research and Development. Efficacy and safety study of nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). Available from: https://clinicaltrials.gov/study/NCT05327114. Accessed 27 Apr 2024.

58.

Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. https://doi.org/10.1038/s41572-021-00321-x.CrossRefPubMed

59.

Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford). 2021;60(4):1784–92. https://doi.org/10.1093/rheumatology/keaa459.CrossRefPubMed

60.

Fasano S, Alves SC, Isenberg DA. Current pharmacological treatment of idiopathic inflammatory myopathies. Expert Rev Clin Pharmacol. 2016;9(4):547–58. https://doi.org/10.1586/17512433.2016.1136561.CrossRefPubMed

61.

Natour AEH, Kivity S. Biological therapies in inflammatory myopathies. Rambam Maimonides Med J. 2023;14(2): e0008. https://doi.org/10.5041/RMMJ.10495.CrossRefPubMedPubMedCentral

62.

Argenx. Study of a study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy (ALKIVIA), Available from: https://clinicaltrials.gov/study/ NCT05523167. Accessed 27 Apr 2024.

63.

Argenx. A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy (ALKIVIA+). Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05979441. Accessed 27 Apr 2024.

64.

Janssen Research & Development, LLC. A study of nipocalimab in participants with active idiopathic inflammatory myopathies (SPIREA). Available from: https://classic.clinicaltrials.gov/ct2/show/ NCT05379634. Accessed 27 Apr 2024.

65.

Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149–64. https://doi.org/10.1111/cei.12271.CrossRefPubMedPubMedCentral

66.

Costello F. Neuromyelitis optica spectrum disorders. Contin Lifelong Learn Neurol. 2022;28(4):1131–70. https://doi.org/10.1212/CON.0000000000001168.CrossRef

67.

Wingerchuk DM, Banwell B, Bennett J L, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89. https://doi.org/10.1212/WNL.0000000000001729.CrossRefPubMedPubMedCentral

68.

Hinson SR, McKeon A, Fryer JP, et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol. 2009;66(9):1164–7. https://doi.org/10.1001/archneurol.2009.188.CrossRefPubMed

69.

Ma X, Kermode AG, Hu X, et al. NMOSD acute attack: understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020;348: 577387. https://doi.org/10.1016/j.jneuroim.2020.577387.CrossRefPubMed

70.

Wang Y, Zhong X, Wang H, et al. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023;30(1):195–203. https://doi.org/10.1111/ene.15561.CrossRefPubMed

71.

Mayasi Y, Takhtani D, Garg N. Leucine-rich glioma-inactivated protein 1 antibody encephalitis: a case report. Neurol Neuroimmunol Neuroinflamm. 2014;1(4): e51. https://doi.org/10.1212/NXI.0000000000000051.CrossRefPubMedPubMedCentral

72.

Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–89. https://doi.org/10.1212/WNL.0b013e318224afde.CrossRefPubMedPubMedCentral

73.

Ward ES, Gelinas D, Dreesen E, et al. Clinical significance of serum albumin and implications of FcRn inhibitor treatment in IgG-mediated autoimmune disorders. Front Immunol. 2022;13: 892534. https://doi.org/10.3389/fimmu.2022.892534.CrossRefPubMedPubMedCentral

74.

Pérez-Ruixo J-J, Yaowei Z, Martine N, et al. Nipocalimab dose selection for a phase 3 study in adult patients with generalized myasthenia gravis (P1–5.018). Neurology. 2023;100(17_Suppl._2):4294. https://doi.org/10.1212/WNL.0000000000203877.CrossRef

Title: FcRn Inhibitor Therapies in Neurologic Diseases
Authors: Nouf Alfaidi
Salama Karmastaji
Alexandria Matic
Vera Bril
Publication date: 09-05-2024
Publisher: Springer International Publishing
Keywords: Myasthenia Gravis
Neuromyelitis Optica Spectrum Disease
Rozanolixizumab
Efgartigimod
FcRn Inhibitor
Published in: CNS Drugs / Issue 6/2024
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-024-01090-3

Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

Open Access
Migraine
Original Research

Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data

Open Access
Clozapine
Original Research

Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety

Post-COVID Syndrome
Original Research

Sex Differences in Adverse Effects of Antiseizure Medications in Adults with Epilepsy: A Systematic Review

Carbamazepine
Systematic Review

Impulse Control Disorders in Parkinson’s Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management

Open Access
Parkinson Disease
Current Opinion

How can you integrate PET into your practice? (Link opens in a new window)

Alzheimer Disease
Independent Medical Education

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

FcRn Inhibitor Therapies in Neurologic Diseases

Abstract

Other articles of this Issue 6/2024

Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data

Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety

Sex Differences in Adverse Effects of Antiseizure Medications in Adults with Epilepsy: A Systematic Review

Impulse Control Disorders in Parkinson’s Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management

How can you integrate PET into your practice? (Link opens in a new window)

Keynote series | Spotlight on menopause

Navigating neuroimaging in Alzheimer disease care

Springer Medicine

Abstract

Please log in to get access to this content